Private Group RLS (USA) Inc. Acquires GE Healthcare’s U.S. Radiopharmacy Network
RLS (USA) Inc., (Radioisotope Life Sciences) has purchased General Electric’s (GE) U.S. radiopharmacy network, making it the largest pure molecular imaging focused firm in the United States. Capitor, (www.capitor.co) a boutique global financial advisory firm, structured and brought the deal to investors, playing a critical part in the years-long negotiation and collaboration between the parties. Financial terms were not disclosed.
The radiopharmacies will continue to supply GE Healthcare molecular imaging products, with RLS leveraging a 10-year distribution partnership agreement. The now privately-owned radiopharmacy network includes a minority ownership by Perceptive Advisors, a $7 billion healthcare specialist investment firm based in New York.
The executive team of RLS is comprised of Chief Executive Officer Werner Gruner, Chief Investment Officer Jaco van Niekerk and Chief Operations Officer Shane Cobb. Mr. Gruner, who has served as executive in various roles within the international financial industry, including the founding of Capitor, comments that “I was intrigued and excited about the possibilities of this healthcare acquisition, beyond the financial aspects of the transaction. I have spent my career providing white-glove investment advisory services to global clients and always believed that customers, no matter the industry, not only deserve, but have a right to demand personalized, timely, high-end service,” adding, “that is why we focus on service, quality and disruptive technology as key factors in our investment strategy.”
The radiopharmacy network includes 31 pharmacies across 18 states, including its current headquarters in Tampa, Florida. Under the direction of Mr. van Niekerk, RLS aims to invest $2 billion over the next decade in expanding its footprint of pharmacies, while continuously investing in cutting-edge scientific and technological advancements. “We invested considerable efforts to ensure a seamless transition precisely because of our service-centric philosophy, including retaining key executive staff, such as Shane Cobb who has more than 30 years of experience in the industry,” stated Mr. van Niekerk, concluding that “RLS is committed to delivering life-saving quality diagnostics and treatment to patients across the nation. To that end, and in light of what we are uncovering regarding the potential long-term effects of organ damage caused by COVID-19, we have instituted a special task force focused on accommodating what could be a surge in demand for specialized diagnostic services.”
Almost five-hundred former GE employees across the country are now part of the RLS family. The company is expected to relocate its headquarters to the east coast of Florida in the near future and is in conversations with various economic development councils as well as municipalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006104/en/
Contact information
Amanda Penebaker
608-345-9420
amanda.penebaker@rls.bio
https://rls.bio/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Published Data Confirms Nemluvio ® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis17.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action on itch and sleep, with significant improvements observed as early as 48 hours after treatment in some patients with atopic dermatitis and prurigo nodularis.1 The findings from post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs were published in the Journal of the European Academy of Dermatology and Venereology. Nemolizumab is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signalling of IL-31.2,5,6 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis.3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in achieving rapid itch response. Atopic dermatitis and prurigo nodularis are debilitating skin conditions that significantly affect quality of life, with symptoms such as per
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 05:00:00 EET | Press release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 04:00:00 EET | Press release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations. SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience. By mode
IDWS 2025 Concludes with Focus on Global Knowledge Exchange, Financial Opportunities, and Scalable Water Solutions16.12.2025 21:03:00 EET | Press release
The 4th Innovation Driven Water Sustainability Conference (IDWS) 2025 concluded on Wednesday in Jeddah, confirming its status as one of the world’s most influential platforms for shaping the future of water innovation, sustainability, and security. Gathering senior global policymakers and international industry leaders, this year’s edition has advanced critical dialogue on safeguarding the planet’s most vital resource, with Saudi Arabia at the forefront. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216483490/en/ Investors, innovators, and global institutions gather in Saudi to outline how capital, collaboration, and governance can accelerate long term water sustainability (Photo: AETOSWire) Among the most consequential engagements were a series of meetings that brought together discussions powered by SWA, centred on shared challenges, knowledge exchange, and exploring opportunities within the global water ecosystem. Att
OAG Appoints ex-Skyscanner Executive Filip Filipov as New Chief Executive Officer16.12.2025 18:00:00 EET | Press release
OAG announces today the appointment of Filip Filipov, ex-Skyscanner executive, as new Chief Executive Officer. Filip Filipov currently serves as the company’s Chief Operating Officer and takes over from Phil Callow who has chosen to step down having completed thirteen transformational years at the helm of OAG to pursue his many other interests. Since joining in 2024, Filipovhas played a leading role in the company’s ambitious next phase of growth and ongoing acceleration. He will now lead OAG into a new era defined by advanced data products and AI-driven intelligence. Before joining OAG, Filipov held senior roles in travel technology and big-data consulting, including on Skyscanner’s executive team. Filip Filipov said: “It’s a privilege to step into this role and lead a company with such a strong heritage and reputation. I’m excited for what’s ahead and committed to serving our customers with the reliability, service, and innovation they depend on.” Chairman of OAG, Gehan Talwatte, com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom